|
|
| | Iluzanebart Basic information |
| | Iluzanebart Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Iluzanebart Usage And Synthesis |
| Uses | Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP)[1]. | | in vivo | Iluzanebart (1-200 mg/kg, ip, single dose) increases microglia proliferation and CSF1R levels in human TREM2 expressing transgenic mice models[1]. | Animal Model: | Human TREM2 expressing transgenic mice models[1] | | Dosage: | 1-200 mg/kg | | Administration: | ip, single dose | | Result: | Increased the number of Ki67 positive microglia, the mean fluorescence intensity (MFI) of microglia with high CSF1R levels and the protein levels of specific chemokines such as IP10 and MIP1α. |
| | References | [1] Larson KC, et al., Rescue of in vitro models of CSF1R-related adult-onset leukodystrophy by iluzanebart: mechanisms and therapeutic implications of TREM2 agonism. J Neuroinflammation. 2025 Jan 31;22(1):26. DOI:10.1186/s12974-025-03346-1 |
| | Iluzanebart Preparation Products And Raw materials |
|